María Santos Romero
Biocomputing and Omics Integration Facility (SBIO) at CBM · CBM
Biography
|
PhD in Molecular Biology. Oncology and Genetics, Pharmacogenomics. Doctoral Researcher at the Spanish National Cancer Research Centre (CNIO) from 2017 to 2021. (Description curated from publicly available data.) |
Profile
| Institution | CBM |
| Position | Data Analyst |
| Home page | https://www.linkedin.com/in/msantosromero/ |
| Contact email | msromero@cbm.csic.es |
| ORCID | 0000-0003-1740-7379 |
BCB Hub
| BCB Committee | Talent attraction and training, Junior Hub |
| BCB Tools | |
| BCB Services | Biocomputing and Omics Integration Facility (SBIO) at CBM |
Publications 19 entries
- Deubiquitinase USP9X loss sensitizes renal cancer cells to mTOR inhibition Article · Jun 2023
- DLST mutations in pheochromocytoma and paraganglioma cause proteome hyposuccinylation and metabolic remodeling Article · 4 May 2023
- Genomic and immune landscape Of metastatic pheochromocytoma and paraganglioma Article · 28 Feb 2023
- Interrogating the Significance of PARP1 Expression and PBRM1 Mutation as Biomarkers for Predicting the Response to Atezolizumab plus Bevacizumab or to Sunitinib in Patients with Clear Cell Renal Cell Carcinoma Article · Sep 2022
- Considerations on diagnosis and surveillance measures of PTEN hamartoma tumor syndrome: clinical and genetic study in a series of Spanish patients Article · 28 Feb 2022
View all (14 more)
- Sunitinib and Evofosfamide ( TH -302) in Systemic Treatment-Naïve Patients with Grade 1/2 Metastatic Pancreatic Neuroendocrine Tumors: The GETNE -1408 Trial Article · 14 Jul 2021
- Prevalence of pathogenic germline variants in patients with metastatic renal cell carcinoma Article · Apr 2021
- Molecular characterization of chromophobe renal cell carcinoma reveals mTOR pathway alterations in patients with poor outcome Article · Dec 2020
- Novel DNMT3A Germline Variant in a Patient with Multiple Paragangliomas and Papillary Thyroid Carcinoma Article · 9 Nov 2020
- CD133 Expression in Medullary Thyroid Cancer Cells Identifies Patients with Poor Prognosis Article · 13 Aug 2020
- A Novel Approach for the Identification of Pharmacogenetic Variants in MT-RNR1 through Next-Generation Sequencing Off-Target Data Article · 2 Jul 2020
- Effect of the Most Relevant CYP3A4 and CYP3A5 Polymorphisms on the Pharmacokinetic Parameters of 10 CYP3A Substrates Article · 22 Apr 2020
- Prognostic and Predictive Value of PBRM1 in Clear Cell Renal Cell Carcinoma Article · 19 Dec 2019
- Hsa‐miR‐139‐5p is a prognostic thyroid cancer marker involved in HNRNPF‐mediated alternative splicing Article · 28 Aug 2019
- PTEN expression and mutations in TSC1 , TSC2 and MTOR are associated with response to rapalogs in patients with renal cell carcinoma Article · 9 Aug 2019
- Integrative multi-omics analysis identifies a prognostic miRNA signature and a targetable miR-21-3p/TSC2/mTOR axis in metastatic pheochromocytoma/paraganglioma Article · 2019
- Gain-of-function mutations in DNMT3A in patients with paraganglioma Article · Dec 2018
- Concomitant Medications and Risk of Chemotherapy-Induced Peripheral Neuropathy Article · 23 Nov 2018
- Novel copy-number variations in pharmacogenes contribute to interindividual differences in drug pharmacokinetics Article · Jun 2018